Abstract
Biomedical investigators use different methods including experimental animals, tissue, and cell cultures as well as computational simulations and clinical studies finding the ways to treat human diseases and disorders. All the mentioned procedures have their own advantages and disadvantages. For instance although animal models provide some drawbacks like difference in biokinetics parameters or extrapolation of results to human, they are more reliable than in vitro tests. The disadvantage of the in vitro procedures is that they are mostly performed on cancerous cell lines that have a substantially abnormal function. Furthermore, although in vitro models are fruitfully used in biological fields, finding an end point, the initial aim of chemical attack, and extrapolation of the effects to the human are some real weaknesses. Absence of biokinetics in in vitro methods may lead to a misinterpretation of the data. The present review has criticized the pros and cons of both methods, especially in the fields of pharmacology, toxicology, and medical sciences.
Keywords: Biokinetics, biological activity, clinical, in silico, in vitro, in vivo, novel biomedical methods, review.
Current Drug Discovery Technologies
Title:From in vitro Experiments to in vivo and Clinical Studies; Pros and Cons
Volume: 12 Issue: 4
Author(s): Soodabeh Saeidnia, Azadeh Manayi and Mohammad Abdollahi
Affiliation:
Keywords: Biokinetics, biological activity, clinical, in silico, in vitro, in vivo, novel biomedical methods, review.
Abstract: Biomedical investigators use different methods including experimental animals, tissue, and cell cultures as well as computational simulations and clinical studies finding the ways to treat human diseases and disorders. All the mentioned procedures have their own advantages and disadvantages. For instance although animal models provide some drawbacks like difference in biokinetics parameters or extrapolation of results to human, they are more reliable than in vitro tests. The disadvantage of the in vitro procedures is that they are mostly performed on cancerous cell lines that have a substantially abnormal function. Furthermore, although in vitro models are fruitfully used in biological fields, finding an end point, the initial aim of chemical attack, and extrapolation of the effects to the human are some real weaknesses. Absence of biokinetics in in vitro methods may lead to a misinterpretation of the data. The present review has criticized the pros and cons of both methods, especially in the fields of pharmacology, toxicology, and medical sciences.
Export Options
About this article
Cite this article as:
Saeidnia Soodabeh, Manayi Azadeh and Abdollahi Mohammad, From in vitro Experiments to in vivo and Clinical Studies; Pros and Cons, Current Drug Discovery Technologies 2015; 12 (4) . https://dx.doi.org/10.2174/1570163813666160114093140
DOI https://dx.doi.org/10.2174/1570163813666160114093140 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aldose Reductase Inhibitory Potential of Several Thiazolyl-thiazolidine- 2,4-Diones
Letters in Drug Design & Discovery Editorial (thematic Issue: Functional Performance of L-Carnosine (β-Alanyl-L-Histidine) and Related Imidazole-Containing Dipeptides. Design and Modern Applications of Drug Delivery Systems (Nanosuspensions of Nanosize Materials, Mucoadhesive Drug Delivery Systems, Formulations of Transdermal Patches for Controlled Drug Delivery)
Recent Patents on Drug Delivery & Formulation Andrographolide Reorganise Hyperglycaemia and Distorted Antioxidant Profile in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population
Cardiovascular & Hematological Agents in Medicinal Chemistry Topics on Pharmacology for Dietitians in Modern Practice
Current Nutrition & Food Science Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe
Current HIV Research Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light of Current Knowledge)
Current Vascular Pharmacology Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects
Current Medicinal Chemistry Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis
Reviews on Recent Clinical Trials The Impact of Oxidative Stress on Islet Transplantation and Monitoring the Graft Survival by Non-Invasive Imaging
Current Medicinal Chemistry Antiplatelet Therapy And Percutaneous Coronary Interventions
Current Cardiology Reviews Endocrine Disruptors and Human Health
Mini-Reviews in Medicinal Chemistry MK-0626, A Dipeptidyl Peptidase-4 Inhibitor, Improves Neovascularization by Increasing Both the Number of Circulating Endothelial Progenitor Cells and Endothelial Nitric Oxide Synthetase Expression
Current Medicinal Chemistry Lymphatics and Inflammation
Current Medicinal Chemistry Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Obesity: A New Pathology to Pay Attention to in Young People
Current Pharmaceutical Design Inhibition of GSK3 Dependent Tau Phosphorylation by Metals
Current Alzheimer Research Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria
Current Vascular Pharmacology Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design